
Kimberly A. Aron
Examiner (ID: 19346, Phone: (571)272-2789 , Office: P/1633 )
| Most Active Art Unit | 1633 |
| Art Unit(s) | 1633, 1636 |
| Total Applications | 517 |
| Issued Applications | 243 |
| Pending Applications | 54 |
| Abandoned Applications | 232 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17946086
[patent_doc_number] => 20220333103
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => GENE VECTOR
[patent_app_type] => utility
[patent_app_number] => 17/855135
[patent_app_country] => US
[patent_app_date] => 2022-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24417
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17855135
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/855135 | Gene vector | Jun 29, 2022 | Issued |
Array
(
[id] => 18093475
[patent_doc_number] => 20220411816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => TRANSPOSITION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM AMYELOIS
[patent_app_type] => utility
[patent_app_number] => 17/847021
[patent_app_country] => US
[patent_app_date] => 2022-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30696
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17847021
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/847021 | Transposition of nucleic acid constructs into eukaryotic genomes with a transposase from amyelois | Jun 21, 2022 | Issued |
Array
(
[id] => 18374379
[patent_doc_number] => 20230149458
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/846868
[patent_app_country] => US
[patent_app_date] => 2022-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 138999
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846868
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/846868 | Articles of manufacture and methods for treatment using adoptive cell therapy | Jun 21, 2022 | Issued |
Array
(
[id] => 17960330
[patent_doc_number] => 20220340910
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => SUGAR CHAIN-RELATED GENE AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/805290
[patent_app_country] => US
[patent_app_date] => 2022-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34369
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17805290
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/805290 | Sugar chain-related gene and use thereof | Jun 2, 2022 | Issued |
Array
(
[id] => 18165542
[patent_doc_number] => 20230032141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-02
[patent_title] => GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING HYDROXYACID OXIDASE 1 (HAO1) AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/832038
[patent_app_country] => US
[patent_app_date] => 2022-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55711
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17832038
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/832038 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING HYDROXYACID OXIDASE 1 (HAO1) AND USES THEREOF | Jun 2, 2022 | Pending |
Array
(
[id] => 18050714
[patent_doc_number] => 11524081
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-13
[patent_title] => Codon optimized REP1 genes and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/740045
[patent_app_country] => US
[patent_app_date] => 2022-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 16377
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17740045
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/740045 | Codon optimized REP1 genes and uses thereof | May 8, 2022 | Issued |
Array
(
[id] => 17792429
[patent_doc_number] => 20220251520
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => AAV VECTORS PRODUCED BY INSECT CELLS COMPRISING REP52 AND REP78 CODING SEQUENCES WITH DIFFERENTIAL CODON BIASES
[patent_app_type] => utility
[patent_app_number] => 17/722275
[patent_app_country] => US
[patent_app_date] => 2022-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13160
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 278
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17722275
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/722275 | AAV vectors produced by insect cells comprising Rep52 and Rep78 coding sequences with differential codon biases | Apr 14, 2022 | Issued |
Array
(
[id] => 20535998
[patent_doc_number] => 12553064
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-02-17
[patent_title] => Methods and compositions for targeted genetic modification through single-step multiple targeting
[patent_app_type] => utility
[patent_app_number] => 17/713696
[patent_app_country] => US
[patent_app_date] => 2022-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 45029
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1223
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17713696
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/713696 | Methods and compositions for targeted genetic modification through single-step multiple targeting | Apr 4, 2022 | Issued |
Array
(
[id] => 20593824
[patent_doc_number] => 12577528
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-17
[patent_title] => Taurine supplemented cell culture medium and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/707017
[patent_app_country] => US
[patent_app_date] => 2022-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 10471
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707017
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/707017 | Taurine supplemented cell culture medium and methods of use | Mar 28, 2022 | Issued |
Array
(
[id] => 19709267
[patent_doc_number] => 20250019409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-16
[patent_title] => POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/283523
[patent_app_country] => US
[patent_app_date] => 2022-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51167
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -94
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283523
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/283523 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | Mar 22, 2022 | Pending |
Array
(
[id] => 17684889
[patent_doc_number] => 20220192181
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => CRYOPRESERVATION OF VIABLE HUMAN SKIN SUBSTITUTES
[patent_app_type] => utility
[patent_app_number] => 17/694245
[patent_app_country] => US
[patent_app_date] => 2022-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11528
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17694245
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/694245 | CRYOPRESERVATION OF VIABLE HUMAN SKIN SUBSTITUTES | Mar 13, 2022 | Abandoned |
Array
(
[id] => 20401275
[patent_doc_number] => 12491235
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-09
[patent_title] => Methods and compositions for treating metabolic imbalance in neurodegenerative disease
[patent_app_type] => utility
[patent_app_number] => 17/574847
[patent_app_country] => US
[patent_app_date] => 2022-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 330
[patent_figures_cnt] => 81
[patent_no_of_words] => 17126
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17574847
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/574847 | Methods and compositions for treating metabolic imbalance in neurodegenerative disease | Jan 12, 2022 | Issued |
Array
(
[id] => 20593880
[patent_doc_number] => 12577584
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-17
[patent_title] => Non-HLA matched humanized NSG mouse model with patient-derived xenograft
[patent_app_type] => utility
[patent_app_number] => 17/569660
[patent_app_country] => US
[patent_app_date] => 2022-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 54
[patent_no_of_words] => 10900
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17569660
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/569660 | Non-HLA matched humanized NSG mouse model with patient-derived xenograft | Jan 5, 2022 | Issued |
Array
(
[id] => 17563490
[patent_doc_number] => 20220127639
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
[patent_app_type] => utility
[patent_app_number] => 17/569788
[patent_app_country] => US
[patent_app_date] => 2022-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14333
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17569788
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/569788 | Non-HLA matched humanized NSG mouse model with patient-derived xenograft | Jan 5, 2022 | Issued |
Array
(
[id] => 20480400
[patent_doc_number] => 12528871
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-20
[patent_title] => Universal immune cells for cancer immunotherapy
[patent_app_type] => utility
[patent_app_number] => 17/647122
[patent_app_country] => US
[patent_app_date] => 2022-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 14088
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17647122
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/647122 | Universal immune cells for cancer immunotherapy | Jan 4, 2022 | Issued |
Array
(
[id] => 18526352
[patent_doc_number] => 11713337
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-01
[patent_title] => Peptide, compositions and method for delivery of agents into cells and tissues
[patent_app_type] => utility
[patent_app_number] => 17/646496
[patent_app_country] => US
[patent_app_date] => 2021-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 50
[patent_figures_cnt] => 24
[patent_no_of_words] => 21775
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17646496
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/646496 | Peptide, compositions and method for delivery of agents into cells and tissues | Dec 29, 2021 | Issued |
Array
(
[id] => 17701987
[patent_doc_number] => 20220201993
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => MICE THAT MAKE HEAVY CHAIN ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/550927
[patent_app_country] => US
[patent_app_date] => 2021-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17816
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17550927
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/550927 | Mice that make heavy chain antibodies | Dec 13, 2021 | Issued |
Array
(
[id] => 17732496
[patent_doc_number] => 20220217955
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => Non-Human Animals Expressing pH-Sensitive Immunoglobulin Sequences
[patent_app_type] => utility
[patent_app_number] => 17/545099
[patent_app_country] => US
[patent_app_date] => 2021-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 84303
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17545099
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/545099 | Non-human animals expressing pH-sensitive immunoglobulin sequences | Dec 7, 2021 | Issued |
Array
(
[id] => 20577355
[patent_doc_number] => 12569592
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-10
[patent_title] => Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
[patent_app_type] => utility
[patent_app_number] => 17/532893
[patent_app_country] => US
[patent_app_date] => 2021-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 36662
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17532893
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/532893 | Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof | Nov 21, 2021 | Issued |
Array
(
[id] => 17399896
[patent_doc_number] => 20220041986
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => Truncated Epiderimal Growth Factor Receptor (EGFRt) for Transduced T Cell Selection
[patent_app_type] => utility
[patent_app_number] => 17/507996
[patent_app_country] => US
[patent_app_date] => 2021-10-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8422
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17507996
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/507996 | Truncated epiderimal growth factor receptor (EGFRt) for transduced t cell selection | Oct 21, 2021 | Issued |